16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

NCT01649375 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

219

Enrollment

INDUSTRY

Sponsor class

Conditions

Anklyosing Spondylitis

Interventions

DRUG: Secukinumab (75 mg)
DRUG: Placebo
DRUG: Secukinumab (150 mg)

Sponsor

Novartis Pharmaceuticals